<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pemetrexed: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pemetrexed: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pemetrexed: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11270" href="/d/html/11270.html" rel="external">see "Pemetrexed: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F207166"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Alimta;</li>
<li>Pemfexy</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867872"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Alimta;</li>
<li>TARO-PEMEtrexed</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F207185"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Antimetabolite;</li>
<li>
                        Antineoplastic Agent, Antimetabolite (Antifolate)</li></ul></div>
<div class="block doa drugH1Div" id="F207168"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> New treatment cycles should not begin unless ANC ≥1,500/mm<sup>3</sup>, platelets ≥100,000/mm<sup>3</sup>, CrCl ≥45 mL/minute, and recovery of nonhematologic toxicity to ≤ grade 2.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Premedication:</i> Start vitamin supplements 1 week before initial pemetrexed dose: Folic acid 400 to 1,000 mcg orally once daily (begin 7 days prior to treatment initiation; continue daily during treatment and for 21 days after last pemetrexed dose) and vitamin B<sub>12</sub> 1,000 mcg IM 7 days prior to treatment initiation and then every 3 cycles. Subsequent vitamin B<sub>12</sub> doses may be administered on the same day as pemetrexed treatments. In patients without preexisting anemia, some data suggest that pemetrexed and cyanocobalamin may be started simultaneously to avoid delaying pemetrexed initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30825389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30825389'])">Ref</a></span>). Administer dexamethasone 4 mg orally twice daily for 3 days, beginning the day before treatment to minimize cutaneous reactions.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4767e758-2865-460b-bc52-db9c99ea9161">Bladder cancer, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bladder cancer, metastatic (off-label use):</b>
<b>IV:</b> 500 mg/m<sup>2</sup> on day 1 of each 21-day cycle until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16849761']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16849761'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b40337c-ce5a-45e3-a7ae-4d056ec67c06">Cervical cancer, recurrent or persistent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cervical cancer, recurrent or persistent (off-label use):</b>
<b>IV:</b> 500 mg/m<sup>2</sup> on day 1 of each 21-day cycle until disease progression or unacceptable toxicity occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19605508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19605508'])">Ref</a></span>) <b>or</b> 900 mg/m<sup>2</sup> on day 1 of each 21-day cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18455781']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18455781'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b00a027-bd66-4d8a-903c-6d47086c0533">Malignant pleural mesothelioma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malignant pleural mesothelioma:</b>
<b>IV:</b> 500 mg/m<sup>2</sup> on day 1 of each 21-day cycle (in combination with cisplatin); continue until disease progression or unacceptable toxicity. American Society of Clinical Oncology guidelines for malignant pleural mesothelioma recommend first-line platinum/pemetrexed-based therapy for 4 to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29346042']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29346042'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing/combinations: </i>
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">500 mg/m<sup>2</sup> on day 1 of each 21-day cycle in combination with carboplatin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16549838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16549838'])">Ref</a></span>) <b>or</b> 500 mg/m<sup>2</sup> on day 1 of each 21-day cycle (in combination with carboplatin) until disease progression, unacceptable toxicity, or for a maximum of 9 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18156144']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18156144'])">Ref</a></span>) <b>or </b> 500 mg/m<sup>2</sup> on day 1 of each 21-day cycle as single-agent therapy until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18594323']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18594323'])">Ref</a></span>) <b>or </b>500 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with cisplatin and bevacizumab) for up to 6 cycles, followed by bevacizumab maintenance therapy until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26719230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26719230'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="882fda81-8f38-458e-aedf-9f25c9891839">Non–small cell lung cancer, nonsquamous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, nonsquamous:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>In combination with cisplatin:</i>
<b>IV: </b>500 mg/m<sup>2</sup> on day 1 of each 21-day cycle (in combination with cisplatin) for up to 6 cycles or until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>In combination with cemiplimab and a platinum (off-label combination): </i>
<b>IV: </b>500 mg/m<sup>2</sup> on day 1 of each 21-day cycle (in combination with cemiplimab and either carboplatin or cisplatin) for 4 cycles, followed by pemetrexed maintenance therapy and cemiplimab until disease progression or unacceptable toxicity, or for up to 108 weeks; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36008722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36008722'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial treatment of metastatic NSCLC:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>In combination with pembrolizumab and a platinum:</i>
<b> IV: </b>500 mg/m<sup>2</sup> on day 1 of each 21-day cycle (in combination with pembrolizumab and either carboplatin or cisplatin) for 4 cycles; following platinum-based therapy, may continue pemetrexed (alone or with pembrolizumab) as maintenance therapy until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29658856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29658856'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>In combination with durvalumab, tremelimumab, and a platinum</i>
<i>(off-label combination)</i>:<b> IV:</b> 500 mg/m<sup>2</sup> on day 1 of each 21-day cycle (in combination with either carboplatin or cisplatin, durvalumab, and tremelimumab) for 4 cycles, followed by optional pemetrexed maintenance therapy (in combination with durvalumab) if eligible; continue until disease progression or unacceptable toxicity; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36327426']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36327426'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance treatment of locally advanced or metastatic NSCLC (after 4 cycles of initial platinum-based therapy):</i>
<b>IV: </b>500 mg/m<sup>2</sup> on day 1 of each 21-day cycle (as a single-agent); continue until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Second-line treatment of recurrent/metastatic disease (after prior chemotherapy):</i>
<b>IV: </b>500 mg/m<sup>2</sup> on day 1 of each 21-day cycle (as a single-agent); continue until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0a26b36c-a0b6-4b1a-ab49-bc843c350fbe">Ovarian cancer, platinum-resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer, platinum-resistant (off-label use):</b>
<b>IV: </b>500 mg/m<sup>2</sup> on day 1 of each 21-day cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19168349']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19168349'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="160917a5-8b33-4ab9-9208-96479f4f625f">Thymic malignancies, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thymic malignancies, metastatic (off-label use):</b>
<b>IV: </b>500 mg/m<sup>2</sup> on day 1 of each 21-day cycle for 6 cycles or until disease progression or unacceptable toxicity occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Loehrer.2006']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Loehrer.2006'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991860"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Kenar D. Jhaveri, MD; Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Kidney impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function: IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Kidney function may be estimated using the Cockcroft-Gault formula. Measures to mitigate nephrotoxicity (eg, avoiding dehydration, nonsteroidal anti-inflammatory drugs, other potentially nephrotoxic agents during pemetrexed maintenance therapy) should be considered. Ibuprofen administration decreases pemetrexed elimination, specifically in CrCl &lt;80 mL/minute; consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥45 mL/minute: <b>IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>). <b>Note:</b> Patients with CrCl 45 to 60 mL/minute may be at increased risk of hematological, GI, and kidney-related toxicities; use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12860935']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12860935'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;45 mL/minute: <b>IV</b>: Use not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). Pharmacokinetic modeling suggests substantially lower doses would be necessary to avoid severe neutropenia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34181276']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34181276'])">Ref</a></span>). Additionally, an increased risk of hematologic toxicity in patients with CrCl &lt;45 mL/minute has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27286996','lexi-content-ref-25659505','lexi-content-ref-16391300']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27286996','lexi-content-ref-25659505','lexi-content-ref-16391300'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Although the correlation of renal function with AUC suggests an increased dose of pemetrexed may be needed in patients with documented ARC, there are no clinical data to support the efficacy or safety of this approach (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b>
<b>IV:</b> Somewhat dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30885337']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30885337'])">Ref</a></span>): Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis: IV:</b> Dialyzability unknown: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT: IV: </b>Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16809156','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16809156','lexi-content-ref-Expert.DOR'])">Ref</a></span>). In a single case report, a patient receiving pemetrexed (in combination with cisplatin) had persistent pemetrexed concentrations in ascites and plasma despite receiving continuous veno-venous hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16809156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16809156'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): IV: </b>Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nephrotoxicity during therapy: </b>Acute kidney injury attributed to single-agent pemetrexed or pemetrexed in combination with other chemotherapy agents has been reported. Causality of acute kidney injury with pemetrexed reported in retrospective analysis and case reports is often confounded by concurrent or recent cisplatin or carboplatin administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25659505','lexi-content-ref-27241854','lexi-content-ref-24986522','lexi-content-ref-28750665']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25659505','lexi-content-ref-27241854','lexi-content-ref-24986522','lexi-content-ref-28750665'])">Ref</a></span>). Consider interrupting pemetrexed therapy if acutely deteriorating kidney function attributable to pemetrexed is suspected (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Additionally, withhold pemetrexed if CrCl falls below 45 mL/minute and do not reinitiate until CrCl is ≥45 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989157"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, elevated AST, AST, or total bilirubin do not appear to affect pemetrexed pharmacokinetics.</p></div>
<div class="block doo drugH1Div" id="F20343890"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup>:</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full, weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F207186"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Dosage modification of other concomitant anticancer agents may also be recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hematologic toxicity:</i> Upon recovery to ANC ≥1,500/mm<sup>3</sup> and platelets ≥100,000/mm<sup>3</sup>, reinitiate therapy as stated below. <b>Note: </b>If ANC &lt;500/mm<sup>3</sup> or platelets &lt;50,000/mm<sup>3</sup> in previous cycles, permanently reduce pemetrexed dose.</p>
<p style="text-indent:-2em;margin-left:4em;">ANC &lt;500/mm<sup>3</sup> and platelets ≥50,000/mm<sup>3</sup>: Reduce pemetrexed dose to 75% of previous dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Platelets &lt;50,000/mm<sup>3</sup>
<b>without bleeding</b>: Reduce pemetrexed dose to 75% of previous dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Platelets &lt;50,000/mm<sup>3</sup>
<b>with bleeding</b>: Reduce pemetrexed dose to 50% of previous dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Recurrent grade 3 or 4 myelosuppression after 2 dose reductions: Discontinue pemetrexed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Nonhematologic toxicity:</i> Withhold treatment until recovery to ≤ grade 2; upon recovery, reinitiate or discontinue therapy as follows:</p>
<p style="text-indent:-2em;margin-left:4em;">Grade 3 or 4 toxicity (excluding mucositis and neurotoxicity): Reduce pemetrexed dose to 75% of previous dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Grade 3 or 4 diarrhea or any diarrhea requiring hospitalization: Reduce pemetrexed dose to 75% of previous dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Grade 3 or 4 mucositis: Reduce pemetrexed dose to 50% of previous dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Grade 3 or 4 neurotoxicity: Permanently discontinue pemetrexed.</p>
<p style="text-indent:-2em;margin-left:4em;">Interstitial pneumonitis: Interrupt therapy and evaluate promptly for acute onset new or progressive pulmonary symptoms (eg, dyspnea, cough, fever); if interstitial pneumonitis is confirmed, permanently discontinue pemetrexed.</p>
<p style="text-indent:-2em;margin-left:4em;">Radiation recall signs/symptoms: Permanently discontinue pemetrexed.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe or life-threatening bullous, blistering, or exfoliating dermatologic toxicity: Permanently discontinue pemetrexed.</p>
<p style="text-indent:-2em;margin-left:4em;">Recurrent grade 3 or 4 nonhematologic toxicity after 2 dose reductions: Permanently discontinue pemetrexed.</p></div>
<div class="block doe drugH1Div" id="F2997988"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;text-align:justify;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F207136"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for monotherapy in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Desquamation (≤14%), skin rash (≤14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (19% to 22%), diarrhea (5% to 13%; grades 3/4: 1%), nausea (12% to 31%; grades 3/4: ≤3%), stomatitis (≤15%; grades 3/4: ≤1%), vomiting (6% to 16%; grades 3/4: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (15% to 19%; grades 3/4: 3% to 5%), neutropenia (6% to 11%; grades 3/4: 3% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (18% to 34%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis (≤15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (6%), erythema multiforme (&lt;5%), pruritus (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (1% to 5%), constipation (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Febrile neutropenia (&lt;5%), thrombocytopenia (8%; grades 3/4: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (8% to 10%), increased serum aspartate aminotransferase (7% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection ( 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Neuropathy (sensory: 9%; motor: &lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (≤5%), increased lacrimation (1% to &lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (8%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Pulmonary embolism (grades 3/4), supraventricular cardiac arrhythmia, syncope (grades 3/4), ventricular tachycardia (grades 3/4)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal obstruction (grades 3/4)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (grades 3/4), pain (grades 3/4)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal failure syndrome</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (may be reported as part of combination chemotherapy regimen):</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous rash, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Colitis, pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pneumonitis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Radiation recall phenomenon</p></div>
<div class="block coi drugH1Div" id="F207149"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Severe hypersensitivity to pemetrexed or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Concomitant yellow fever vaccine.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F207134"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Pemetrexed may cause severe myelosuppression, including anemia, neutropenia, thrombocytopenia and/or pancytopenia; myelosuppression is often dose-limiting. Severe myelosuppression may require blood transfusion or may lead to neutropenic infection. Prophylactic folic acid and vitamin B<sub>12</sub> supplements are necessary to reduce hematologic toxicity, febrile neutropenia and infection; initiate supplementation 1 week before the first dose of pemetrexed and continue for 21 days after the last pemetrexed dose (the risk for myelosuppression is higher in patients who did not receive vitamin supplementation).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cutaneous reactions: Serious and occasionally fatal, bullous, blistering, and exfoliative dermatologic toxicity may occur; pretreatment with dexamethasone is necessary to reduce the incidence and severity of cutaneous reactions. Rarely, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicity: GI toxicity may occur; prophylactic folic acid and vitamin B<sub>12</sub> supplements are necessary to reduce GI toxicity. Initiate supplementation 1 week before the first dose of pemetrexed and continue for 21 days after the last pemetrexed dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity (including allergic reaction) has been reported with pemetrexed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotoxicity: Pemetrexed may cause severe (and potentially fatal) kidney toxicity (kidney toxicity may occur with single-agent pemetrexed or when used in combination with other chemotherapy agents).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Interstitial pneumonitis has been observed; may be serious and/or fatal. Signs/symptoms indicative of interstitial pneumonitis may include acute onset new or progressive pulmonary symptoms such as dyspnea, cough, or fever.</p>
<p style="text-indent:-2em;margin-left:4em;">• Radiation recall: Radiation recall may occur in patients administered pemetrexed who received radiation previously (weeks to years).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Pemetrexed is primarily cleared by the kidneys; decreased renal function results in increased toxicity. Concurrent nephrotoxic medications may result in delayed pemetrexed clearance.</p>
<p style="text-indent:-2em;margin-left:4em;">• Third space fluid: Although the effect of third space fluid on pemetrexed pharmacokinetics has not been fully defined, studies have determined pemetrexed concentrations in patients with mild to moderate ascites/pleural effusions were similar to concentrations in trials of patients without third space fluid accumulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Ibuprofen: Ibuprofen may reduce the clearance of pemetrexed. In patients with CrCl 45 to 79 mL/minute, interrupt ibuprofen therapy 2 days prior to, during, and 2 days after pemetrexed therapy. If concomitant use cannot be avoided, monitor for myelosuppression, renal, and gastrointestinal toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p></div>
<div class="block prod-avail drugH1Div" id="F58278043"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Pemetrexed 100 mg/10 mL, 500 mg/50 mL, 1,000 mg/100 mL single dose vials: FDA approved May 2023; anticipated availability is currently unknown. Information pertaining to this product within the monograph is pending revision. Consult prescribing information for additional information.</p></div>
<div class="block foc drugH1Div" id="F207144"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pemfexy: 500 mg/20 mL (20 mL) [contains propylene glycol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/4 mL (4 mL); 500 mg/20 mL (20 mL); 1 g/40 mL (40 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as disodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/4 mL (4 mL); 500 mg/20 mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as disodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/4 mL (4 mL); 500 mg/20 mL (20 mL); 850 mg/34 mL (34 mL); 1 g/40 mL (40 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alimta: 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg (1 ea); 500 mg (1 ea); 1000 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alimta: 100 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg (1 ea); 500 mg (1 ea); 750 mg (1 ea); 1000 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F2998602"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F4589208"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (PEMEtrexed Disodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/40mL (per mL): $27.00 - $31.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/4 mL (per mL): $30.31 - $210.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/20 mL (per mL): $27.33 - $210.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">850MG/34ML (per mL): $27.33</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (PEMEtrexed Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/40mL (per mL): $56.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/4 mL (per mL): $59.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/20 mL (per mL): $59.46</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Pemfexy Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/20 mL (per mL): $252.03</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Alimta Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $970.32</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $4,851.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (PEMEtrexed Disodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $13.96 - $856.16</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $60.18 - $4,280.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $866.26 - $6,421.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $222.84 - $8,561.57</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867873"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alimta: 100 mg (1 ea); 500 mg ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg (1 ea); 500 mg (1 ea); 1000 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F207146"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Infuse over 10 minutes. When used in combination with platinum-based therapy (cisplatin or carboplatin), administer pemetrexed prior to the platinum. Administer pemetrexed after pembrolizumab if administered on the same day. When used in combination with durvalumab and tremelimumab, administer tremelimumab first, followed by durvalumab and then pemetrexed on the day of dosing.</p></div>
<div class="block hazard drugH1Div" id="F49132756"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F207145"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Malignant pleural mesothelioma:</b> Initial treatment of malignant pleural mesothelioma (in combination with cisplatin) that is unresectable or in patients who are not otherwise candidates for curative surgery.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-small cell lung cancer, nonsquamous:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Initial treatment of locally advanced or metastatic <b>non</b>squamous non-small cell lung cancer (NSCLC) (in combination with cisplatin).</p>
<p style="text-indent:-2em;margin-left:4em;">Initial treatment of metastatic, <b>non</b>squamous NSCLC (in combination with platinum chemotherapy and pembrolizumab) in patients with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance treatment (single-agent) of locally advanced or metastatic <b>non</b>squamous NSCLC if no progression after 4 cycles of platinum-based first-line therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Single-agent treatment (after prior chemotherapy) of recurrent/metastatic <b>non</b>squamous NSCLC.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitation of use: Pemetrexed is not indicated for the treatment of <b>squamous</b> cell NSCLC.</p></div>
<div class="block off-label drugH1Div" id="F25725967"><span class="drugH1">Use: Off-Label: Adult</span><p>Bladder cancer, metastatic; Cervical cancer, persistent or recurrent; Ovarian cancer, platinum-resistant; Thymic malignancies, metastatic</p></div>
<div class="block mst drugH1Div" id="F3401929"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">PEMEtrexed may be confused with methotrexate, pembrolizumab, PRALAtrexate</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299833"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F207138"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibuprofen: May increase the serum concentration of PEMEtrexed. Management: In patients with an estimated creatinine clearance of 45 to 79 mL/min, avoid ibuprofen for 2 days before, the day of, and 2 days following the administration of pemetrexed. Monitor for increased pemetrexed toxicities if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: PEMEtrexed may increase the serum concentration of Methotrexate.  Management: Avoid coadministration of pemetrexed and methotrexate if possible. If coadministration is required, monitor closely for methotrexate toxicities (eg, hematological, gastrointestinal, nephrotoxicity toxicities).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitisinone: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pyrimethamine: May enhance the adverse/toxic effect of PEMEtrexed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaborbactam: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49315178"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to treatment initiation in patients who could become pregnant. Patients who could become pregnant should use effective contraception during treatment and for at least 6 months after the last pemetrexed dose. Patients with partners who could become pregnant should use effective contraception during treatment and for 3 months after the last pemetrexed dose. Pemetrexed may impair fertility in males.</p></div>
<div class="block pri drugH1Div" id="F207151"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on findings in animal reproduction studies and on the mechanism of action, pemetrexed may cause fetal harm if administered during pregnancy.</p></div>
<div class="block brc drugH1Div" id="F2997980"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if pemetrexed is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment and for 1 week after the last pemetrexed dose.</p></div>
<div class="block mop drugH1Div" id="F207142"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;">CBC with differential and platelets (at the beginning of each cycle, and on days 8 and 15 of each cycle if clinically indicated); renal function tests (serum creatinine, creatinine clearance, BUN; prior to each cycle and as needed) total bilirubin, ALT, AST (periodic). Verify pregnancy status prior to treatment initiation (in patients who could become pregnant). Monitor for signs/symptoms of mucositis and diarrhea, pulmonary toxicity, dermatologic toxicity, and radiation recall (monitor for inflammation or blistering in areas of prior radiation treatment).</p>
<p style="text-indent:0em;margin-top:2em;">The American Society of Clinical Oncology hepatitis B screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends hepatitis B virus (HBV) screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F207133"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Pemetrexed is an antifolate; it disrupts folate-dependent metabolic processes essential for cell replication. Pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), glycinamide ribonucleotide formyltransferase (GARFT), and aminoimidazole carboxamide ribonucleotide formyltransferase (AICARFT), the enzymes involved in folate metabolism and DNA synthesis, resulting in inhibition of purine and thymidine nucleotide and protein synthesis.</p></div>
<div class="block phk drugH1Div" id="F207148"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 16.1 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 81%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Minimal</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Normal renal function: 3.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (70% to 90% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51192072"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Pemetrexed clearance decreases and AUC increases as renal function decreases; in patients with CrCl of 45, 50, and 80 mL/minute, AUC was increased 65%, 54%, and 13%, respectively, compared with patients with CrCl of 100 mL/minute.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F207153"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Pemetrexed spc</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Alltrexed | Ekel | Enzastar | Holista | Lidoras | Martxel | Paxequime | Pemetrexed gp pharm | Pemetrexed ima | Pemetrexed varifarma | Peymetrel | Praxed | Sukuba | Tepenac | Trexam | Venusted | Xulia</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Armisarte | Pemegerolan | Pemetrexed accord | Pemetrexed ever pharma | Pemetrexed fresenius kabi | Pemetrexed krka | Pemetrexed sandoz | Pemetrexed stada | Pemetrexed zentiva</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Dbl pemetrexed | Pemetrexed accord | Pemetrexed aft | Pemetrexed apotex | Pemetrexed juno | Pemetrexed myx | Pemetrexed sandoz | Pemetrexed sun | Reladdin | Tevatrexed</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Alimta</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Armisarte | Pemetrexed accord | Pemetrexed eg | Pemetrexed ever pharma | Pemetrexed Fresenius Kabi | Pemetrexed fresenius kabi | Pemetrexed hospira | Pemetrexed krka | Pemetrexed mylan | Pemetrexed sandoz</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Armisarte | Pemetrexed alvogen | Pemetrexed heaton | Pemetrexed sandoz</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Atred | Eroxym | Mesotem | Pemeglenn | Pemetrexede | Pemetrexede dissodico | Pemetrexede dissodico heptaidratado | Pemtryx | Plexeden | Sukhi</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Amtiris | Pemetrexed accord | Pemetrexed mylan | Pemetrexed pfizer | Pemetrexed sandoz | Pemetrexed Spirig HC | Pemetrexed Teva | Pemetrexed zentiva</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Pemetrexed</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Ao tian cheng | Jie bai li | Pu lai le | Sai zhen | Yi luo ze</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Cacitab | Enzastar | Genetrexed | Lekarna | Martxel | Nextrexed | Paxib | Pemeker | Pemeta | Pemetrexed | Pemetrexed kemex | Pemetrexseven | Pemgem | Pemintas | Pexed | Pexitaz | Pleurex | Prelonex | Prelun | Revotrain | Sumitrexed | Taxitan | Tremzated | Venprex</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Armisarte | Pemetrexed accord | Pemetrexed ever pharma | Pemetrexed fresenius kabi | Pemetrexed glenmark | Pemetrexed heaton | Pemetrexed krka | Pemetrexed sandoz | Pemetrexed Teva | Pemetrexed zentiva | Trixid</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Albotiva | Alimta | Pemetrexed accord | Pemetrexed beta | Pemetrexed ever pharma | Pemetrexed fresenius kabi | Pemetrexed Fresenius Kabi | Pemetrexed hexal | Pemetrexed hospira | Pemetrexed medac | Pemetrexed mylan | Pemetrexed neocorp | Pemetrexed ribosepharm | Pemetrexed seacross | Pemetrexed stada | Pemetrexed sun | Pemetrexed tad | Pemetrexed zentiva</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Alimta</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Enzastar | Pemetrexed | Sukuba</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Pemetrexed accord | Pemetrexed alvogen | Pemetrexed medac | Pemetrexed sandoz</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Alimta</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Armisarte | Mintayax | Pemetrexed accord | Pemetrexed Aurovit | Pemetrexed ebewe | Pemetrexed ever pharma | Pemetrexed Fresenius Kabi | Pemetrexed hospira | Pemetrexed mylan | Pemetrexed sala | Pemetrexed Stadage | Pemetrexed sun | Pemetrexed tillomed</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Pemetrexed | Pemxcel</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Pemetrexed accord | Pemetrexed ever pharma | Pemetrexed Fresenius Kabi | Pemetrexed hexal | Pemetrexed medac</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Armisarte | Pemetrexed | Pemetrexed accord | Pemetrexed ever pharma | Pemetrexed Fresenius Kabi | Pemetrexed mylan | Pemetrexed zentiva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Pemetrexed | Pemetrexed hospira | Pemetrexed sandoz | Pemetrexed seacross</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Alimta</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Dbl pemetrexed | Pemenon</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Alimta</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Armisarte | Pemetrexed accord | Pemetrexed pharmaswiss | Pemetrexed sandoz | Pemetrexed stada | Pemetrexed Teva | Trixid</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Fontrexed | Kabipem | Pemtero | Primexa</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Armisarte | Pemetrexed | Pemetrexed krka | Pemetrexed mylan</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Alimta</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Adpem | Kabipem | Pamifect | Pemanat | Pemecad | Pemeplast | Pemetero | Pemex | Pemexar | Pemgem | Pemmet | Pemotide | Pemxcel | Pexetrust | Pexitaz | Pleumet | Prexx | Relitrexed | Strimta | Symyx | Temeran | Zupemed</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Armisarte | Pemetrexed accord | Pemetrexed eg | Pemetrexed ever pharma | Pemetrexed Fresenius Kabi | Pemetrexed hospira | Pemetrexed mylan | Pemetrexed reddy | Pemetrexed sandoz | Pemetrexed sun</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Pemitra | Trixem</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Pemetrexed</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Alimta</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alexia | Algik | Alimta | Alimxed | Mainta | Pelimta | Pemebit | Pemecin | Pemecine | Pemed | Pemed s | Pemirex | Pemta | Pemxed | Pfizer pemetrexed</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Alimta</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Pleutrex</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Pemetrexed accord | Pemetrexed alvogen | Pemetrexed ebewe | Pemetrexed fresenius kabi | Pemetrexed medac | Pemetrexed mylan | Pemetrexed zentiva</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Pemetrexed accord | Pemetrexed alvogen | Pemetrexed fresenius kabi</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Pemetrexed zenith</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Asocapul | Bemetad | Empet | Itara | Martxel | Pemetrexed | Pexitaz | Tec pred | Tremzated | Trexedical | Virplazit | Zulamed</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Accord pemetrexed | Ontrex | Pemenon | Podoxred</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Armisarte | Pemetrexed | Pemetrexed accord | Pemetrexed b medical | Pemetrexed cf | Pemetrexed ever pharma | Pemetrexed fresenius kabi | Pemetrexed krka | Pemetrexed mylan | Pemetrexed sandoz | Pemetrexed zentiva</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Pemetrexed | Pemetrexed accord | Pemetrexed Fresenius Kabi | Pemetrexed fresenius kabi | Pemetrexed medac | Pemetrexed sandoz</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Dbl pemetrexed | Pemetrexed | Pemetrexed juno</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Enzastar | Metanex | Pemeker | Pemetrexed</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Pemirex | Pexate</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Algik | Alimta | Maclimta | Pemetrexed sandoz | Proxed</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Pemetreksed sun | Pemetrexed accord | Pemetrexed alvogen | Pemetrexed Fresenius Kabi | Pemetrexed glenmark | Pemetrexed sandoz</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Pemetrexed</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Pemetrexed sandoz | Pemetrexed stada | Pemetrexedo accord | Pemetrexedo ebewe | Pemetrexedo ever pharma | Pemetrexedo fresenius kabi | Pemetrexedo Refta</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Enzastar | Holista | Lekarna | Lidoras | Mytrex | Pemeker | Pemetrexed bauel top | Pemetrexed imedic | Pemetrexed intas | Pemetrexed kemex | Pemetrexed medicine | Pemetrexed prosalud | Pemetrexed sandoz | Pemetrexed varifarma | Venusted</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Alimta</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Armisarte | Pemetrexed accord | Pemetrexed dr reddys | Pemetrexed stada | Pemetrexed sun | Pemetrexed zentiva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Folitrex | Ispolat | Pemelan | Pemetrexed | Pemetrexed J | Pemetrexed nativ | Pemetrexed TL | Pemjem | Verotrexed</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Almetra | Pemetrexed spc | Pemitra</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Armisarte | Pemetrexed | Pemetrexed accord | Pemetrexed ever pharma | Pemetrexed fresenius kabi | Pemetrexed hexal | Pemetrexed hospira | Pemetrexed mylan | Pemetrexed reig jofre | Pemetrexed stada</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Alimta</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Pemetreksed accord | Pemetreksed krka</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Pemetrexed accord | Pemetrexed ever pharma | Pemetrexed fresenius kabi | Pemetrexed generics | Pemetrexed glenmark | Pemetrexed pharmevid | Pemetrexed sandoz | Pemetrexed stada | Pemetrexed Teva | Trixid</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Emetex | Pemetrex venus</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Cytolim | Pemetrexed neapolis | Trexam</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Pemtrex | Prexet | Relitrexed</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Apeta | Pemeda | Pemetrexed | Pexeda</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Pemetrexed mb | Pemetro</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Alimta | Pemetrexed</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Pemetrexed</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Pemehope</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aliloma | Alimta | Pemetrexed accord | Pemetrexed fresenius kabi | Pemject | PEMTORI IV | Terexta</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alimta.1">
<a name="Alimta.1"></a>Alimta (pemetrexed) [prescribing information]. Indianapolis, IN: Lilly USA LLC; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alimta.2">
<a name="Alimta.2"></a>Alimta (pemetrexed) [product monograph]. Mississauga, Ontario, Canada: Actavis Pharma Company; July 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27286996">
<a name="27286996"></a>Ando Y, Hayashi T, Ujita M, et al. Effect of renal function on pemetrexed-induced haematotoxicity. <i>Cancer Chemother Pharmacol</i>. 2016;78(1):183-189. doi:10.1007/s00280-016-3078-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/27286996/pubmed" id="27286996" target="_blank">27286996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin</i>
<i>Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34181276">
<a name="34181276"></a>Boosman RJ, Dorlo TPC, de Rouw N, et al. Toxicity of pemetrexed during renal impairment explained - implications for safe treatment. <i>Int J Cancer</i>. 2021;149(8):1576-1584. doi:10.1002/ijc.33721<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/34181276/pubmed" id="34181276" target="_blank">34181276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16809156">
<a name="16809156"></a>Brandes JC, Grossman SA, Ahmad H. Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature. <i>Cancer Invest</i>. 2006;24(3):283-287. doi:10.1080/07357900600629567<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/16809156/pubmed" id="16809156" target="_blank">16809156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18156144">
<a name="18156144"></a>Castagneto B, Botta M, Aitini E, et al, “Phase II Study of Pemetrexed in Combination With Carboplatin in Patients With Malignant Pleural Mesothelioma (MPM),” <i>Ann Oncol</i>, 2008, 19(2):370-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/18156144/pubmed" id="18156144" target="_blank">18156144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16549838">
<a name="16549838"></a>Ceresoli GL, Zucali PA, Favaretto AG, et al, “Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma,” <i>J Clin Oncol</i>, 2006, 24(9):1443-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/16549838/pubmed" id="16549838" target="_blank">16549838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25659505">
<a name="25659505"></a>Chauvet S, Courbebaisse M, Ronco P, Plaisier E. Pemetrexed-induced acute kidney injury leading to chronic kidney disease. <i>Clin Nephrol</i>. 2014;82(6):402-406. doi:10.5414/CN107921<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/25659505/pubmed" id="25659505" target="_blank">25659505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25659505">
<a name="25659505"></a>Chen CY, Lin JW, Huang JW, et al. Estimated creatinine clearance rate is associated with the treatment effectiveness and toxicity of pemetrexed as continuation maintenance therapy for advanced nonsquamous non-small-cell lung cancer. <i>Clin Lung Cancer</i>. 2015;16(6):e131-e140. doi:10.1016/j.cllc.2015.01.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/25659505/pubmed" id="25659505" target="_blank">25659505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19767093">
<a name="19767093"></a>Ciuleanu T, Brodowicz T, Zielinski C, et al, “Maintenance Pemetrexed Plus Best Supportive Care versus Placebo Plus Best Supportive Care for Non-Small-Cell Lung Cancer: A Randomised, Double-Blind, Phase 3 Study,” <i>Lancet</i>, 2009, 374(9699):1432-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/19767093/pubmed" id="19767093" target="_blank">19767093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30885337">
<a name="30885337"></a>de Rouw N, Croes S, Posthuma R, et al. Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis. <i>Lung Cancer</i>. 2019;130:156-158. doi:10.1016/j.lungcan.2019.01.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/30885337/pubmed" id="30885337" target="_blank">30885337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27241854">
<a name="27241854"></a>Fung E, Anand S, Bhalla V. Pemetrexed-induced nephrogenic diabetes insipidus. <i>Am J Kidney Dis</i>. 2016;68(4):628-632. doi:10.1053/j.ajkd.2016.04.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/27241854/pubmed" id="27241854" target="_blank">27241854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29658856">
<a name="29658856"></a>Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. <i>N Engl J Med</i>. 2018;378(22):2078-2092. doi: 10.1056/NEJMoa1801005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/29658856/pubmed" id="29658856" target="_blank">29658856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36008722">
<a name="36008722"></a>Gogishvili M, Melkadze T, Makharadze T, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. <i>Nat Med.</i> 2022;28(11):2374-2380. doi:10.1038/s41591-022-01977-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/36008722/pubmed" id="36008722" target="_blank">36008722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19433683">
<a name="19433683"></a>Grønberg BH, Bremnes RM, Fløtten O, et al, “Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin as First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer,” <i>J Clin Oncol</i>, 2009, 27(19):3217-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/19433683/pubmed" id="19433683" target="_blank">19433683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15117980">
<a name="15117980"></a>Hanna N, Shepherd FA, Fossella FV, et al, “Randomized Phase III Trial of Pemetrexed versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy,” <i>J Clin Oncol</i>, 2004, 22(9):1589-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/15117980/pubmed" id="15117980" target="_blank">15117980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AstraZeneca.1">
<a name="AstraZeneca.1"></a>Imfinzi (durvalumab) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278. doi:10.1542/peds.99.2.268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18375898">
<a name="18375898"></a>Jassem J, Ramlau R, Santoro A, et al, “Phase III Trial of Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma,” <i>J Clin Oncol</i>, 2008, 26(10):1698-704.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/18375898/pubmed" id="18375898" target="_blank">18375898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36327426">
<a name="36327426"></a>Johnson ML, Cho BC, Luft A, et al; POSEIDON investigators. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study. <i>J Clin Oncol.</i> Published online November 3, 2022. doi:10.1200/JCO.22.00975<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/36327426/pubmed" id="36327426" target="_blank">36327426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29346042">
<a name="29346042"></a>Kindler HL, Ismaila N, Armato SG 3rd, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2018;36(13):1343-1373. doi:10.1200/JCO.2017.76.6394<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/29346042/pubmed" id="29346042" target="_blank">29346042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27745820">
<a name="27745820"></a>Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. <i>Lancet Oncol</i>. 2016;17(11):1497-1508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/27745820/pubmed" id="27745820" target="_blank">27745820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Loehrer.2006">
<a name="Loehrer.2006"></a>Loehrer PJ, Yiannoutsos CT, Dropcho S, et al, “A Phase II Trial of Pemetrexed in Patients With Recurrent Thymoma or Thymic Carcinoma,” <i>J Clin Oncol</i>, 2006, 24(suppl):7079 [abstract 7079 from 2006 ASCO Annual Meeting].</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19605508">
<a name="19605508"></a>Lorusso D, Ferrandina G, Pignata S, et al, “Evaluation of Pemetrexed (Alimta, LY231514) as Second-Line Chemotherapy in Persistent or Recurrent Carcinoma of the Cervix: The CERVIX 1 Study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group,” <i>Ann Oncol</i>, 2010, 21(1):61-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/19605508/pubmed" id="19605508" target="_blank">19605508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26324367">
<a name="26324367"></a>Masters GA, Temin S, Azzoli CG. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update [published correction appears in <i>J Clin Oncol</i>. 2016;34(11):1287]. <i>J Clin Oncol</i>. 2015;33(30):3488-3515.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/26324367/pubmed" id="26324367" target="_blank">26324367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18455781">
<a name="18455781"></a>Miller DS, Blessing JA, Bodurka DC, et al, “Evaluation of Pemetrexed (Alimta, LY231514) as Second Line Chemotherapy in Persistent or Recurrent Carcinoma of the Cervix: A Phase II Study of the Gynecologic Oncology Group,” <i>Gynecol Oncol</i>, 2008, 110(1):65-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/18455781/pubmed" id="18455781" target="_blank">18455781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19332726">
<a name="19332726"></a>Miller DS, Blessing JA, Krasner CN, et al, “Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group,” <i>J Clin Oncol</i>, 2009, 27(16):2686-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/19332726/pubmed" id="19332726" target="_blank">19332726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16391300">
<a name="16391300"></a>Mita AC, Sweeney CJ, Baker SD, et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. <i>J Clin Oncol</i>. 2006;24(4):552-562.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/16391300/pubmed" id="16391300" target="_blank">16391300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pemetrexed.1">
<a name="Pemetrexed.1"></a>Pemetrexed injection 100 mg/4 mL, 500 mg/20 mL, and 1,000 mg/40 mL [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pemetrexed.2">
<a name="Pemetrexed.2"></a>Pemetrexed injection 100 mg/4 mL, 500 mg/20 mL, 850 mg/34 mL, and 1,000 mg/40 mL [prescribing information]. Durham, NC: Accord Healthcare Inc; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pemetrexed.3">
<a name="Pemetrexed.3"></a>Pemetrexed injection [prescribing information]. Parsippany, NJ: Actavis Pharma, Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pemetrexed.4">
<a name="Pemetrexed.4"></a>Pemetrexed injection 100 mg/vial, 500 mg/vial, 750 mg/vial, and 1 gram/vial [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA LLC; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pemfexy.1">
<a name="Pemfexy.1"></a>Pemfexy (pemetrexed) [prescribing information]. Woodcliff Lake, NJ: Eagle Pharmaceuticals Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24986522">
<a name="24986522"></a>Rombolà G, Vaira F, Trezzi M, Chiappini N, Falqui V, Londrino F. Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage. <i>J Nephrol</i>. 2015;28(2):187-191. doi:10.1007/s40620-014-0117-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/24986522/pubmed" id="24986522" target="_blank">24986522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12860935">
<a name="12860935"></a>Rusch VW, “Pemetrexed and Cisplatin for Malignant Pleural Mesothelioma: A New Standard of Care?” <i>J Clin Oncol</i>, 2003, 21(14):2629-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/12860935/pubmed" id="12860935" target="_blank">12860935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12860935">
<a name="12860935"></a>Sandhu G, Adattini J, Armstrong Gordon E, O’Neill N; ADDIKD Guideline Working Group. International consensus guideline for anticancer drug dosing in kidney dysfunction 2022. https://www.eviq.org.au/clinical-resources/addikd-guideline/4174-anticancer-drug-dosing-in-kidney-dysfunction. Published 2022. Accessed November 9, 2023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/12860935/pubmed" id="12860935" target="_blank">12860935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28750665">
<a name="28750665"></a>Sbitti Y, Chahdi H, Slimani K, et al. Renal damage induced by pemetrexed causing drug discontinuation: a case report and review of the literature. <i>J Med</i>
<i>Case Rep</i>. 2017;11(1):182. doi:10.1186/s13256-017-1348-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/28750665/pubmed" id="28750665" target="_blank">28750665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18506025">
<a name="18506025"></a>Scagliotti GV, Parikh P, von Pawel J, et al, “Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lun Cancer,”<i>J Clin Oncol</i>, 2008, 26(21):3543-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/18506025/pubmed" id="18506025" target="_blank">18506025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20859133">
<a name="20859133"></a>Schmitt J, Loehrer PJ Sr. The Role of Chemotherapy in Advanced Thymoma. <i>J Thorac Oncol</i>. 2010;5(10)(suppl 4):357-360.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/20859133/pubmed" id="20859133" target="_blank">20859133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30825389">
<a name="30825389"></a>Singh N, Baldi M, Kaur J, et al. Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: the PEMVITASTART randomized trial. <i>Cancer</i>. 2019;125(13):2203-2212. doi:10.1002/cncr.32028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/30825389/pubmed" id="30825389" target="_blank">30825389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19720897">
<a name="19720897"></a>Socinski MA, Smit EF, Lorigan P, et al. Phase III study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer. <i>J Clin Oncol</i>. 2009;27(28):4787-4792.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/19720897/pubmed" id="19720897" target="_blank">19720897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16849761">
<a name="16849761"></a>Sweeney CJ, Roth BJ, Kabbinavar FF, et al. Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium. <i>J Clin Oncol</i>. 2006;24(21):3451-3457.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/16849761/pubmed" id="16849761" target="_blank">16849761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16428497">
<a name="16428497"></a>Sweeney CJ, Takimoto CH, Latz JE, et al. Two Drug Interaction Studies Evaluating the Pharmacokinetics and Toxicity of Pemetrexed When Coadministered With Aspirin or Ibuprofen in Patients With Advanced Cancer. <i>Clin Cancer Res</i>. 2006;12(2):536-542.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/16428497/pubmed" id="16428497" target="_blank">16428497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18594323">
<a name="18594323"></a>Taylor P, Castagneto B, Dark G, et al. Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients With Malignant Pleural Mesothelioma: Results of an International Expanded Access Program. <i>J Thorac Oncol</i>. 2008;3(7):764-771.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/18594323/pubmed" id="18594323" target="_blank">18594323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin</i>
<i>Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19168349">
<a name="19168349"></a>Vergote I, Calvert H, Kania M, et al. A Randomised, Double-Blind, Phase II Study of Two Doses of Pemetrexed in the Treatment of Platinum-Resistant, Epithelial Ovarian or Primary Peritoneal Cancer. <i>Eur J Cancer</i>. 2009;45(8):1415-1423.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/19168349/pubmed" id="19168349" target="_blank">19168349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26719230">
<a name="26719230"></a>Zalcman G, Mazieres J, Margery J, et al; French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i>. 2016;387(10026):1405-1414. doi:10.1016/S0140-6736(15)01238-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/26719230/pubmed" id="26719230" target="_blank">26719230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity.<i> Semin Dial</i>. 2007;20(3):217-219. doi:10.1111/j.1525-139X.2007.00280.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemetrexed-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10098 Version 409.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
